Breaking News Instant updates and real-time market news.

NVS

Novartis

$89.84

0.32 (0.36%)

14:43
11/15/19
11/15
14:43
11/15/19
14:43

Novartis receives FDA approval for BLA for Adakveo injection

The FDA has approved Novartis' Adakveo as a treatment to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease, according to a post the agency's website. Reference Link

  • 07

    Dec

NVS Novartis
$89.84

0.32 (0.36%)

10/15/19
BOFA
10/15/19
NO CHANGE
BOFA
Europe 1 List changes at BofA/Merrill
BofA/Merrill added Roche (RHHBY) and Sanofi (SNY) to the Europe 1 List and removed AstraZeneca.
11/12/19
COWN
11/12/19
NO CHANGE
Target $100
COWN
Outperform
Novartis remains a top pharma pick, catalysts cited at Cowen
Cowen analyst Steve Scala said Novartis remains his top pick in pharma for 2019 following strong Q3 results and positive insights into many of its drugs. The analyst said there are many upcoming events through year-end including December's R&D update meeting, EU approvals of Zolgensma and Beovu, and key data readouts. Scala reiterated his Outperform rating and $100 price target on Novartis shares.
11/14/19
WBLR
11/14/19
INITIATION
WBLR
Market Perform
William Blair says Ionis fairly valued on Spinraza headwinds
William Blair analyst Myles Minter initiated coverage of Ionis Pharmaceuticals with a Market Perform rating and $58 fair value estimate. Spinraza, which is marketed by Biogen (BIIB), generates about $2B in revenue per year and has revolutionized the treatment of spinal muscular atrophy, but its long-term growth potential faces headwinds, Minter tells investors in a research note. The analyst anticipates the recent approval of Novartis's (NVS) Zolgensma, an SMA gene therapy, will erode Spinraza's market share of new-start type-1 SMA patients. But more concerning, according to Minter, is the potential 2020 U.S. approval of Roche's (RHHBY) risdiplam, which he believes could erode Spinraza's total market share of type-2/3 patients given a more favorable oral route of delivery. The analyst sees Ionis shares as fairly valued at current levels given the near-term headwinds for its commercial franchise.
11/14/19
ROTH
11/14/19
NO CHANGE
ROTH
Intec Pharma may pursue partnership after failed trial, says Roth Capital
Roth Capital analyst Scott Henry maintained a Neutral rating on Intec Pharma (NTEC), and lowered his price target on shares to 85c from $1.00, after the company reported "disappointing" Q3 results that were within the firm's expectations. The analyst believes that after Intec's AP-CD/LD Parkinson's trial failed to demonstrate a statistically significant benefit, the company may pursue a partnership over the next six months, which "would be viewed positive relative to current expectations." The analyst also noted that the Novartis (NVS) program appears less likely to continue, but a Novartis opt-in "would be considered a material catalyst for shares."

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,749.41

8.82 (0.51%)

13:08
12/06/19
12/06
13:08
12/06/19
13:08
Periodicals
Amazon says U.K. soccer streams brought record Prime sign-ups, Guardian says »

Amazon has said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKR

Baker Hughes

$22.28

0.14 (0.63%)

13:05
12/06/19
12/06
13:05
12/06/19
13:05
Hot Stocks
Baker Hughes reports U.S. rig count down 3 to 799 rigs »

Baker Hughes reports the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$89.77

-0.14 (-0.16%)

, PSN

Parsons

$40.51

0.66 (1.66%)

13:00
12/06/19
12/06
13:00
12/06/19
13:00
Recommendations
Leidos, Parsons analyst commentary  »

Wells says investors…

LDOS

Leidos

$89.77

-0.14 (-0.16%)

PSN

Parsons

$40.51

0.66 (1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

SPY

SPDR S&P 500 ETF Trust

$315.21

3.17 (1.02%)

, VOO

Vanguard S&P 500 ETF

$289.57

2.94 (1.03%)

12:58
12/06/19
12/06
12:58
12/06/19
12:58
Technical Analysis
On The Fly: ETF fund flow highlights »

For the week flows to the…

SPY

SPDR S&P 500 ETF Trust

$315.21

3.17 (1.02%)

VOO

Vanguard S&P 500 ETF

$289.57

2.94 (1.03%)

XLY

Consumer Discretionary Sector SPDR

$121.97

1.19 (0.99%)

XLI

Industrial Select Sector SPDR

$81.21

1.08 (1.35%)

IEF

iShares 7-10 Year Treasury Bond ETF

$110.99

-0.34 (-0.31%)

GLD

SPDR Gold Shares

$137.61

-1.4 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$234.00

0.56 (0.24%)

, JNJ

Johnson & Johnson

$141.00

1.43 (1.02%)

12:53
12/06/19
12/06
12:53
12/06/19
12:53
Hot Stocks
FDA approves Amgen's Avsola »

The U.S. Food and Drug…

AMGN

Amgen

$234.00

0.56 (0.24%)

JNJ

Johnson & Johnson

$141.00

1.43 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

SYPR

Sypris Solutions

$0.82

(0.00%)

, UTX

United Technologies

$147.18

1.87 (1.29%)

12:52
12/06/19
12/06
12:52
12/06/19
12:52
Hot Stocks
Sypris subsidiary wins contracts with United Technologies' Collins Aerospace »

Sypris Electronics, a…

SYPR

Sypris Solutions

$0.82

(0.00%)

UTX

United Technologies

$147.18

1.87 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

LDOS

Leidos

$89.47

-0.44 (-0.49%)

12:49
12/06/19
12/06
12:49
12/06/19
12:49
Hot Stocks
Leidos among team awarded DOE contract for Hanford site services »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMU

Immunomedics

$20.38

1.86 (10.04%)

12:45
12/06/19
12/06
12:45
12/06/19
12:45
Options
Immunomedics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

12:45
12/06/19
12/06
12:45
12/06/19
12:45
General news
Breaking General news story  »

Week of 12/6 Baker-Hughes…

12:45
12/06/19
12/06
12:45
12/06/19
12:45
General news
Breaking General news story  »

Week of 12/6 Baker-Hughes…

12:40
12/06/19
12/06
12:40
12/06/19
12:40
General news
Treasury's $25 B 2-year FRN reopening stopped at 0.245% »

Treasury's $25 B…

12:40
12/06/19
12/06
12:40
12/06/19
12:40
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

12:30
12/06/19
12/06
12:30
12/06/19
12:30
General news
Treasury's $25 B 2-year FRN reopening stopped at 0.245% »

Treasury's $25 B…

PIR

Pier 1 Imports

$7.70

-0.27 (-3.39%)

12:22
12/06/19
12/06
12:22
12/06/19
12:22
Periodicals
Pier 1 hired Guggenheim amid concerns over debt, Debtwire reports »

Pier 1 Imports has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLA

Medallia

$29.11

-0.68 (-2.28%)

12:19
12/06/19
12/06
12:19
12/06/19
12:19
Recommendations
Medallia analyst commentary  »

Oppenheimer says would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

PIR

Pier 1 Imports

$7.92

-0.05 (-0.63%)

12:19
12/06/19
12/06
12:19
12/06/19
12:19
Periodicals
Breaking Periodicals news story on Pier 1 Imports »

Pier 1 hired financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
12/06/19
12/06
12:17
12/06/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
12/06/19
12/06
12:16
12/06/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$60.70

1.195 (2.01%)

, XLRN

Acceleron

$48.58

-0.08 (-0.16%)

12:08
12/06/19
12/06
12:08
12/06/19
12:08
Hot Stocks
Bristol-Myers, Acceleron: FDA says Reblozyl will not be reviewed at ODAC meeting »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$60.70

1.195 (2.01%)

XLRN

Acceleron

$48.58

-0.08 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 04

    Apr

MNTA

Momenta

$17.53

0.68 (4.04%)

12:04
12/06/19
12/06
12:04
12/06/19
12:04
Hot Stocks
Momenta granted orphan status for hemolytic anemia treatment »

The FDA granted Momenta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 16

    Dec

EA

Electronic Arts

$102.74

0.66 (0.65%)

, ATVI

Activision Blizzard

$55.08

0.09 (0.16%)

12:03
12/06/19
12/06
12:03
12/06/19
12:03
Conference/Events
Wedbush digital media analyst to hold an analyst/industry conference call »

Digital Media Analyst…

EA

Electronic Arts

$102.74

0.66 (0.65%)

ATVI

Activision Blizzard

$55.08

0.09 (0.16%)

GME

GameStop

$6.46

0.1 (1.57%)

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$123.21

-0.69 (-0.56%)

UBSFY

Ubisoft

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 13

    Dec

PRVL

Prevail Therapeutics

$14.02

-0.03 (-0.21%)

12:02
12/06/19
12/06
12:02
12/06/19
12:02
Hot Stocks
Prevail Therapeutics granted orphan status for dementia treatment »

The FDA granted Prevail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEI

Weidai

$4.10

-0.35 (-7.87%)

12:00
12/06/19
12/06
12:00
12/06/19
12:00
Hot Stocks
Weidai falls -8.3% »

Weidai is down -8.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PD

PagerDuty

$21.79

-3.2 (-12.81%)

12:00
12/06/19
12/06
12:00
12/06/19
12:00
Hot Stocks
PagerDuty falls -12.8% »

PagerDuty is down -12.8%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YEXT

Yext

$14.02

-2.595 (-15.62%)

12:00
12/06/19
12/06
12:00
12/06/19
12:00
Hot Stocks
Yext falls -15.4% »

Yext is down -15.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.